Cipla, a medicines developer and retailer, and Kemwell Biopharma, a contract manufacturer, intend to produce biosimilars for lung disorders.
Two India-based companies said they have formed a partnership to develop biosimilars for respiratory disease. Their goal is to sell these biosimilars in global markets.
Cipla, based in Mumbai, and Kemwell Biopharma, of Bengaluru, will pair their complementary strengths in product development, clinical development, regulatory filings, manufacturing, and commercialization to develop the biosimilars pipeline, they said.
“This development reinforces our strength as leaders in respiratory therapy and is in line with our aspiration of global lung leadership,” Umag Vohra, managing director and CEO of Cipla, said in a statement.
Cipla is a lung disease specialist with products on the international markets for asthma, chronic obstructive pulmonary disease, allergic rhinitis, and other conditions. The company also produces medicines across multiple other therapeutic categories, including diabetes, women’s health, and tuberculosis.
Besides India, the company has facilities in Africa and North America. The company’s plant in Durban, South Africa, was recently vandalized and looted during the political violence over the jailing of former president Jacob Zuma, but has since reopened.
Kemwell is a contract biologics development and manufacturing company. Kemwell boasts facilities designed in collaboration with German expertise and has partnered with Bayer, GlaxoSmithKline, Merck, Novartis, and Pfizer, according to its website. Kemwell has manufacturing plants in Sweden.
For companies in the developing world, it is important to reassure international clients and markets that facilities and products meet high standards.
Phase 1 Study Finds Comparable PK, PD Parameters in Biosimilar GP40141 vs Reference Romiplostim
November 25th 2023A phase 1 analysis confirms that romiplostim biosimilar candidate GP40141 has comparable pharmacokinetic (PK) and pharmacodynamic (PD) parameters in healthy volunteers compared with the reference product.
Biosimilars Regulatory Roundup for September 2023—Podcast Edition
October 1st 2023On this episode, we discuss several regulatory updates from around the globe, including some European and Japanese approvals, the FDA’s 2-day workshop on the present science behind clinical efficacy testing for biosimilars, and streamlining biosimilar development.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).
How Streamlining Development Can Save the US Biosimilar Industry
August 20th 2023On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, expanded on ways to make biosimilar development faster and cheaper without compromising on safety and efficacy and how these practices can ensure a sustainable market for the future.
Part 3: Study Questions Usefulness of Clinical Efficacy Trials for Oncology Biosimilars in Europe
November 16th 2023In part 3 of a 3-part series for Global Biosimilars Week, The Center for Biosimilars® reviews an analysis investigating whether clinical efficacy studies have an impact on prescribing decisions for oncology biosimilars across Europe.
Eye on Pharma: Denosumab Biosimilar Data; COA Forms New Committee; IGBA and WHO Collaborate
November 8th 2023Samsung Bioepis releases data for its denosumab biosimilar candidate; the Community Oncology Alliance (COA) forms the Drug Policy and Regulation Committee; the International Generic and Biosimilar Association (IGBA) and the World Health Organization (WHO) collaborate on a new initiative.